Income statement
USD
Annual
| Metric | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 83K |
| Gross Profit | 0 | 0 | 0 | 0 | 22K |
| Operating Income | -6M | -13M | -20M | -22M | -8M |
| EBITDA | -6M | -13M | -20M | -18M | -8M |
| Net Income | -10M | -21M | -20M | -22M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0005
+0.00% today
1Y Change
-0.00%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 241 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VIA Pharmaceuticals, Inc. (VIAP) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 0.0% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +55.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +55.2%, free cash flow +48.6% with operating margin 0.0% and ROIC 0.0%. Stock Foundry combines VIAP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VIAP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VIAP Max Drawdown
-0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VIAP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$83.3K
FY Net Income
-$8.6M
+60.5% YoY
Free Cash Flow
-$8.3M
+57.5% YoY
Revenue Growth
+0.0%
EPS Growth
+55.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 83K |
| Gross Profit | 0 | 0 | 0 | 0 | 22K |
| Operating Income | -6M | -13M | -20M | -22M | -8M |
| EBITDA | -6M | -13M | -20M | -18M | -8M |
| Net Income | -10M | -21M | -20M | -22M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|
| Cash & Equivalents | 84K | 2M | 4M | 23M | 3M |
| Total Assets | 500K | 3M | 5M | 24M | 4M |
| Total Liabilities | 19M | 14M | 3M | 4M | 10M |
| Shareholder Equity | -18M | -11M | 2M | 21M | -6M |
| Total Debt | 14M | 10M | 0 | 2K | 8M |
| Net Debt | 14M | 8M | -4M | -23M | 5M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
8M
+56.9% YoY
Capital Expenditures
8K
+98.8% YoY
Free Cash Flow
8M
+57.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
64.7%
Debt / Equity
-0.76x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.